To determine whether CDDO-TFEA mediates the cell viability of GBM8401 cells, we treated each glioma cell line with increasing doses of CDDO-TFEA (0, 1, 1.5, and 2 μM) for 24 h and then measured cell viability by using peripheral blood (PB). The gene discussed is TFE3; the disease is glioma.